Generic Pharmaceuticals Company Investment Opportunity in New York, United States

- The two main partners sold their stake in a previous company almost 10 years back and have now created their own new company.

- They hold over 40 patents and are on the verge of their first approved generic complex injectable drug in a couple of months.

- The facility was inspected very recently by the FDA and passed.

- We have 5 drugs pending approval with a total market value of over USD 4B and only a few competitors.

- The company should be worth USD 2B in another 3 years.

- The business has not generated any revenue because we have been in the process of R&D in developing these drugs for the past 6 years and have invested over USD 40 million in the business.

We have 5 drugs in the pipeline. Information is attached. The drugs are all generic and we are only 1 of 2/3 facilities in the United States that are able to manufacture complex injectables.

Specialized equipment for the manufacturing of complex injectables. The business also owns land of 27 acres.

27 acres of own land, 50,000 sqft of building space in East Windsor.

Friends, family, and distribution contracts.

USD 4.2M - outstanding loan on the existing building.

USD 3M - 2nd deposit on specialized equipment that is being manufactured in Europe.

There are 7 shareholders in the business.